Farmakološke mogućnosti u liječenju plućne arterijske hipertenzije

master's thesis

• Title (english): Pharmacological Options for the Treatment of Pulmonary Arterial Hypertension
• Author: Nikolina Škreblin
• Mentor: Lidija Bach-Rojecky (mentor)
• Committee member: Lidija Bach-Rojecky (predsjednik povjerenstva)
• Committee member: Željka Vanić (član povjerenstva)
• Committee member: Marijana Zovko Končić (član povjerenstva)
• Granter: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmacology); Zagreb
• Defense date and country: 2019-06-14, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract

Plućna arterijska hipertenzija je progresivna bolest pluća s vrlo velikom smrtnošću koja je posljedica zatajenja srca.
Budući da se javlja rijetko u populaciji, spada u skupinu rijetkih bolesti (orphan diseases). Zahvaljujući napretku u
razumijevanju patobiologije u podlozi ove bolesti razvijeni su brojni lijekovi koji djeluju na jedan od tri ključna
signalna puta u glatkim mišićnim stanicama krvnih žila pluća – prostaciklinski, endotelinski i put dušik oksida. Tako
su glavne skupine lijekova koji se koriste u terapiji antagonisti endotelinskih receptora, inhibitori fosfodiesteraze 5,
stimulator topljive gvanilat ciklaze, sintetski analozi prostaciklina i neprostaciklinski agonisti IP receptora. Svi ovi
lijekovi smanjuju endotelnu disfunkciju i dovode do vazodilatacije, ali pritom slabo djeluju na vaskularno
remodeliranje. Zbog toga su prvenstveno simptomatska terapija koja blago usporava napredovanje bolesti, što je
poticaj daljnim istraživanjima novih terapijskih opcija kako bi usporili ili zaustavili progresiju bolesti djelujući na više
patofizioloških putova te u konačnici omogućili oboljelima učinkovitiju i sigurniju terapiju te veću kvalitetu života.

Abstract (english)

Pulmonary arterial hypertension is a progressive lung disease with very high mortality resulting from heart failure. It
is a very serious disease that occurs rarely in the population and therefore belongs to the group of orphan diseases.
Thanks to the progression in understanding the patobiology underlying this disease many new drugs have been
developed. Existing approved drugs act on the major signal pathways in smooth muscle cells. Main groups of drugs
used in the therapy of pulmonary arterial hypertension are endothelin receptors antagonists, phosphodiesterase 5
inhibitors, stimulators of soluble guanylate cyclase, synthetic analogs of prostacyclin and agonists of IP receptors. All
of these drugs reduce endothelial dysfunction and lead to vasodilation, but have little effect on stopping vascular
remodeling. Because drugs which have been approved do not cure the disease but only reduce the symptoms
further researches continue in order to find new therapeutic options.

• Keywords: plućna arterijska hipertenzija; endotelinski put; put dušikovog oksida; put prostaciklina; antagonisti receptora endotelina; inhibitori fosfodiesteraze 5; agonisti gvanilat ciklaze; analozi prostaciklina
• Keywords (english): pulmonary arterial hypertension; endothelin pathway; nitric oxide pathway; serotonine pathway in pulmonary arterial hypertension; prostacyclin pathway; endothelin receptor antagonists; phosphodiesterase 5 inhibitors; guanilat cyclase agonists; prostacyclin analogs
• Language: croatian
• URN:NBN: urn:nbn:hr:163:478627
• Study programme: Title: Pharmacy; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: magistar/magistra farmacije (magistar/magistra farmacije)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2020-02-24 09:21:34